Could a much-delayed COVID-19 shot finally win over religious vaccine skeptics? That’s the question swirling around a vaccine made by Novavax, a Maryland biotech firm that submitted its request to the US Food and Drug Administration last month for emergency use authorization of its COVID-19 shot, also known as NVX-CoV2373. Although more than a year behind competitors such as Moderna and Pfizer/BioNTech, which were both cleared for emergency use in late 2020, Novavax’s two-dose vaccine has already been approved for use in other countries such as the UK, and the company hopes to aid global inoculation efforts. But Novavax may...